Abstract

In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).

Keywords

ObesityAgonistMedicineGlucagon-like peptide-1EndocrinologyDiabetes mellitusReceptorInternal medicineDiseaseType 2 diabetes

MeSH Terms

AdultAnti-Obesity AgentsDose-Response RelationshipDrugDouble-Blind MethodGastric Inhibitory PolypeptideGlucagon-Like PeptidesHumansInjectionsSubcutaneousObesityTreatment OutcomeWeight LossTirzepatide

Affiliated Institutions

Related Publications

Publication Info

Year
2022
Type
article
Volume
387
Issue
3
Pages
205-216
Citations
2460
Access
Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2460
OpenAlex
233
Influential
2365
CrossRef

Cite This

Ania M. Jastreboff, Louis J. Aronne, Nadia N. Ahmad et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine , 387 (3) , 205-216. https://doi.org/10.1056/nejmoa2206038

Identifiers

DOI
10.1056/nejmoa2206038
PMID
35658024

Data Quality

Data completeness: 90%